Related Experiment Video
Updated: Jul 25, 2026
09:16
Detection of a CDH1 Rare Transcript Variant in Fresh-frozen Gastric Cancer Tissues by Chip-based Digital PCR
Published on: February 5, 2018
6.6K
Increased Expression of PHGDH and Prognostic Significance in Colorectal Cancer
Xiao-Qin Jia1, Shu Zhang2, Hui-Jun Zhu2
1Department of Pathology, Yangzhou University, Yangzhou, Jiangsu, China.
Translational Oncology
|June 9, 2016
Summary
Phosphoglycerate dehydrogenase (PHGDH) is highly expressed in colorectal cancer (CRC) tissues. High PHGDH protein levels correlate with advanced disease and predict poor patient outcomes, suggesting its utility in identifying high-risk CRC patients.
Area of Science:
- Oncology
- Cancer Metabolism
- Molecular Diagnostics
Background:
- Phosphoglycerate dehydrogenase (PHGDH) is implicated in metabolic reprogramming in various cancers.
- Its role in colorectal cancer (CRC) and association with clinical outcomes are not well-defined.
Purpose of the Study:
- To investigate PHGDH expression in CRC tissues.
- To determine the correlation between PHGDH expression and clinicopathological features.
- To evaluate the prognostic significance of PHGDH in CRC patients.
Main Methods:
- PHGDH protein expression was assessed using tissue microarray immunohistochemistry (TMA-IHC) in 193 CRC and adjacent tissue pairs.
- PHGDH mRNA levels were quantified using quantitative reverse transcription PCR (qRT-PCR) in 23 fresh CRC tissue pairs.
- Clinicopathological data and survival information were analyzed.
Main Results:
- PHGDH mRNA and protein were significantly upregulated in CRC tissues compared to adjacent non-tumor tissues.
- High PHGDH protein expression was associated with advanced TNM stage and larger tumor size.
- Multivariate analysis identified PHGDH expression, tumor differentiation, and TNM stage as independent prognostic factors.
- High PHGDH expression correlated with poorer survival in CRC patients.
Conclusions:
- PHGDH is overexpressed in colorectal cancer.
- PHGDH protein expression serves as a potential biomarker for identifying high-risk CRC patients.
- Targeting PHGDH may offer therapeutic strategies for CRC.
